Training Dendritic Cells Through Oral Therapy to Restore Immune Balance
- Developing orally delivered immune biomodulators that selectively reprogram dendritic cells within the gut mucosa to drive systemic immune resetting
- Demonstrating how targeted conditioning of intestinal dendritic cells induces tolerogenic pathways, restores regulatory T-cell activity, and exerts downstream control of B-cell hyperactivation
- Summarizing key preclinical and emerging clinical findings, discuss platform design principles, and outline how oral immune therapies can provide safer, more durable, and more accessible treatment options for autoimmune and inflammatory diseases